KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer

@article{Tie2011KRASMI,
  title={KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer},
  author={Jeanne Tie and Lara Rachel Lipton and Jayesh Desai and Peter Gibbs and Robert N. Jorissen and Michael Christie and Katharine J. Drummond and Benjamin Thomson and Val Usatoff and Peter M. Evans and Adrian W. Pick and Simon R. Knight and Peter W. G. Carne and Roger J. Berry and Adrian L. Polglase and Paul J. McMurrick and Qi Zhao and Dana Busam and Robert Strausberg and Enric Domingo and Ian P. M. Tomlinson and Rachel S. Midgley and David J Kerr and Oliver M. Sieber},
  journal={Clinical Cancer Research},
  year={2011},
  volume={17},
  pages={1122 - 1130}
}
Purpose: Oncogene mutations contribute to colorectal cancer development. We searched for differences in oncogene mutation profiles between colorectal cancer metastases from different sites and evaluated these as markers for site of relapse. Experimental Design: One hundred colorectal cancer metastases were screened for mutations in 19 oncogenes, and further 61 metastases and 87 matched primary cancers were analyzed for genes with identified mutations. Mutation prevalence was compared between (a… 
View on AACR
clincancerres.aacrjournals.org
182 Citations
Highly Influential Citations
11
Background Citations
69
Methods Citations
7
Results Citations
19

182 Citations

Citation Type

Citation Type

Association between KRAS mutation and lung metastasis in advanced colorectal cancer
TLDR
Lung metastasis was more likely to develop during the disease course in patients whose tumours had a KRAS mutation than in those whose tumour did not have a KRas mutation, which may have an impact on decision making for surgical resection of metastatic disease.
KRAS mutation in lung metastases from colorectal cancer: prognostic implications
TLDR
KRAS mutation is a negative prognostic factor in mCRC patients undergoing LM and administration of adjuvant chemotherapy after lung metastasectomy (LM) significantly improved both PFS and OS.
Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer
TLDR
Data indicates that different patterns of distant spread are associated with specific biomarker alterations and may represent different molecular subtypes of colorectal cancer, however, underlying mechanisms of metastasis formation in different anatomic sites remains unclear.
Impact of somatic mutations on patterns of metastasis in colorectal cancer.
TLDR
Current understanding of associations between mutational activation of the KRAS, BRAF, PIK3CA, and NRAS oncogenes and clinical outcomes and metastatic patterns of mCRC is described.
Gene heterogeneity in metastasis of colorectal cancer to the lung.
RAS mutation acts as a biomarker during colorectal cancer course in forming the lung metastasis
TLDR
Lung metastasis was more likely to develop during the CRC course in patients whose tumor had a RAS mutation than in those having no RAS mutations.
Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients.
TLDR
Large-sample studies stratified by clinical stage and KRAS subtype are urgently warranted to accurately evaluate mutational variations in CTCs compared to primary and metastatic CRC cells.
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer
TLDR
Patients with either KRAS or PIK3CA mutations are more susceptible to distant metastasis and these two mutations might be used as independent predictors of distant metastatic CRC.
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
TLDR
BRAF mutation is associated with an extremely poor median RFS after liver resection and with higher probability of relapse and death, and knowledge of BRAF mutational status may optimise clinical decision making in mCRC patients potentially candidate to hepatic surgery.
KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary
TLDR
This study examined KRAS, NRAS, BRAF and PIK3CA mutations in 21 patients who were treated with FOLFOX as adjuvant therapy for stage III/IV colorectal cancer following curative resection and suggested that adjUvant FOL FOX may provide a selection pressure favoring a chemotherapy-resistant subset enriched for KRAS mutations while on balance, preventing liver recurrences of patients with KRAS wild-type primary tumours.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
TLDR
A role for KRAS mutations in the propensity of primary colorectal tumors to metastasize to the lung is suggested.
KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases
TLDR
An important role for KRAS activation in colorectal cancer progression is suggested and continued efforts to develop KRAS pathway inhibitors for this disease are supported.
Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver
TLDR
To study the possible role of ras oncogene activation in the dissemination of colon cancer, point mutations in codons 12, 13 and 61 in K‐ and N‐ras in 3 groups of tumors were determined and most mutations were found in the K‐ras gene.
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.
TLDR
KRAS mutations are a predictor of resistance to cetuximab therapy and are associated with a worse prognosis, and the EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment.
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.
TLDR
This population-based study demonstrates important relationships between Ki-ras mutations and stage, survival, tumor location, and gender.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
TLDR
BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
Prognostic Significance of Microsatellite Instability and Ki-ras Mutation Type in Stage II Colorectal Cancer
TLDR
MS+ and Ki-ras mutation type are not useful markers for the identification of high-risk stage II CRC patients and further prospective and/or cohort studies are required to determine whether these molecular changes have predictive value for survival benefit from 5-fluorouracil-based adjuvant chemotherapy.
Colorectal carcinoma and brain metastasis: Distribution, treatment, and survival
TLDR
Surgical removal of colorectal metastatic brain lesions results in significantly increased survival time, regardless of the status of the noncerebral systemic disease.
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
  • R. Amado, M. Wolf, +9 authors David Chang
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
TLDR
Patients with a colorectal tumor bearing mutated K-ras did not benefit from cetuximab, whereas patients with a tumor bearing wild-type K-ra did benefit fromcetuxIMab.
...
1
2
3
4
5
...